131 related articles for article (PubMed ID: 16685529)
21. Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.
Vegeler RC; Yip-Schneider MT; Ralstin M; Wu H; Crooks PA; Neelakantan S; Nakshatri H; Sweeney CJ; Schmidt CM
J Surg Res; 2007 Nov; 143(1):169-76. PubMed ID: 17950089
[TBL] [Abstract][Full Text] [Related]
22. [Report of two cases with pleural effusion and ascites that responded dramatically to the combination of thalidomide, celecoxib, irinotecan, and CDDP infused in thoracic and abdominal cavities].
Hada M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):613-7. PubMed ID: 15114711
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
Innocenti F; Undevia SD; RamÃrez J; Mani S; Schilsky RL; Vogelzang NJ; Prado M; Ratain MJ
Clin Pharmacol Ther; 2004 Nov; 76(5):490-502. PubMed ID: 15536463
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Pan CX; Loehrer P; Seitz D; Helft P; Juliar B; Ansari R; Pletcher W; Vinson J; Cheng L; Sweeney C
Oncology; 2005; 69(1):63-70. PubMed ID: 16088234
[TBL] [Abstract][Full Text] [Related]
26. Effect of thalidomide on gastrointestinal toxic effects of irinotecan.
Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M
Lancet; 2000 Aug; 356(9229):566-7. PubMed ID: 10950238
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9.
Shishodia S; Aggarwal BB
Cancer Res; 2004 Jul; 64(14):5004-12. PubMed ID: 15256475
[TBL] [Abstract][Full Text] [Related]
28. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
[TBL] [Abstract][Full Text] [Related]
29. Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Li W; Zhai L; Tang Y; Cai J; Liu M; Zhang J
Oncol Res; 2012; 20(2-3):49-59. PubMed ID: 23193911
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan and thalidomide in metastatic colorectal cancer.
Govindarajan R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):29-32. PubMed ID: 11204671
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.
Natale RB
Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):22-6. PubMed ID: 12886870
[TBL] [Abstract][Full Text] [Related]
32. Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.
Gajjar A; Chintagumpala MM; Bowers DC; Jones-Wallace D; Stewart CF; Crews KR
Cancer; 2003 May; 97(9 Suppl):2374-80. PubMed ID: 12712459
[TBL] [Abstract][Full Text] [Related]
33. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
34. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
Kaneko S; Kaneko M; Fukushima T
Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
[TBL] [Abstract][Full Text] [Related]
35. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.
Chester JD; Joel SP; Cheeseman SL; Hall GD; Braun MS; Perry J; Davis T; Button CJ; Seymour MT
J Clin Oncol; 2003 Mar; 21(6):1125-32. PubMed ID: 12637480
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
[TBL] [Abstract][Full Text] [Related]
38. Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors.
Furman WL; Crews KR; Billups C; Wu J; Gajjar AJ; Daw NC; Patrick CC; Rodriguez-Galindo C; Stewart CF; Dome JS; Panetta JC; Houghton PJ; Santana VM
J Clin Oncol; 2006 Feb; 24(4):563-70. PubMed ID: 16446328
[TBL] [Abstract][Full Text] [Related]
39. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
